Analyzing non-sentinel axillary metastases in patients with T3-T4 cN0 early breast cancer and tumor-involved sentinel lymph nodes undergoing breast-conserving therapy or mastectomy.
Fabian RiedelJoerg HeilManuel FeisstMareike ModerowAlexandra von AuChristoph DomschkeLaura MichelBenedikt SchaefgenMichael GolattaAndré HennigsPublished in: Breast cancer research and treatment (2020)
The cALND rates have decreased substantially in routine care in patients with 'extended' ACOSOG Z0011 eligibility criteria. Axillary tumor burden is higher in these patients than in the ACOSOG Z0011 trial.
Keyphrases
- lymph node
- early breast cancer
- neoadjuvant chemotherapy
- sentinel lymph node
- end stage renal disease
- healthcare
- ejection fraction
- newly diagnosed
- clinical trial
- chronic kidney disease
- palliative care
- peritoneal dialysis
- stem cells
- prognostic factors
- ultrasound guided
- clinical practice
- randomized controlled trial
- lymph node metastasis
- squamous cell carcinoma
- radiation therapy
- patient reported outcomes
- mesenchymal stem cells
- chronic pain
- pain management
- bone marrow